Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Coleman

Showing results (51-60 of 510) with videos related to

Pageof 51
Sort By:
Journal of Critical Care|March 25, 2008
Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysisEffie L Kuti, Aarti A Patel, Craig I Coleman
Journal of Clinical Pharmacology|January 7, 2006
The impact of suppressing the renin-angiotensin system on atrial fibrillationJames S Kalus, Craig I Coleman, C Michael White
Patient Related Outcome Measures|February 20, 2016
Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohortMatthew F Sidovar, Brendan L Limone, Craig I Coleman
Plos One|October 12, 2012
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillationSoyon Lee, Rachel Mullin, Jon Blazawski, et al.
Pharmacotherapy|April 22, 2005
Probable topical permethrin-induced neck dystoniaCraig I Coleman, Effie L Gillespie, C Michael White
Diabetes Research and Clinical Practice|February 27, 2009
The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: a meta-analysisWilliam L Baker, Erica L Baker, Craig I Coleman
Current Medical Research and Opinion|November 15, 2011
Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosisCraig I Coleman, Diana M Sobieraj, Lawrence N Marinucci
Microbiome Research Reports|December 4, 2023
Modeling microbiota-associated human diseases: from minimal models to complex systemsDoriane Aguanno, Amira Metwaly, Olivia I Coleman, et al.
Thrombosis and Haemostasis|June 23, 2017
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolismCraig I Coleman, Thomas J Bunz, Alexander G G Turpie
European Journal of Haematology|January 12, 2020
Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysisBenjamin Miao, Nitesh Sood, Thomas J Bunz, et al.
Pageof 51

Showing results (51-60 of 510) with videos related to

Sort By:
Pageof 51
Journal of Critical Care|March 25, 2008
Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysisEffie L Kuti, Aarti A Patel, Craig I Coleman
Journal of Clinical Pharmacology|January 7, 2006
The impact of suppressing the renin-angiotensin system on atrial fibrillationJames S Kalus, Craig I Coleman, C Michael White
Patient Related Outcome Measures|February 20, 2016
Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohortMatthew F Sidovar, Brendan L Limone, Craig I Coleman
Plos One|October 12, 2012
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillationSoyon Lee, Rachel Mullin, Jon Blazawski, et al.
Pharmacotherapy|April 22, 2005
Probable topical permethrin-induced neck dystoniaCraig I Coleman, Effie L Gillespie, C Michael White
Diabetes Research and Clinical Practice|February 27, 2009
The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: a meta-analysisWilliam L Baker, Erica L Baker, Craig I Coleman
Current Medical Research and Opinion|November 15, 2011
Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosisCraig I Coleman, Diana M Sobieraj, Lawrence N Marinucci
Microbiome Research Reports|December 4, 2023
Modeling microbiota-associated human diseases: from minimal models to complex systemsDoriane Aguanno, Amira Metwaly, Olivia I Coleman, et al.
Thrombosis and Haemostasis|June 23, 2017
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolismCraig I Coleman, Thomas J Bunz, Alexander G G Turpie
European Journal of Haematology|January 12, 2020
Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysisBenjamin Miao, Nitesh Sood, Thomas J Bunz, et al.
Pageof 51